Novel compounds and compositions as protease inhibitors
申请人:——
公开号:US20020052378A1
公开(公告)日:2002-05-02
The present invention relates to novel cysteine protease inhibitors of Formula I:
1
the pharmaceutically acceptable salts and N-oxide derivatives thereof, their use as therapeutic agents and methods of making them.
Room Temperature, Reductive Alkylation of Activated Methylene Compounds: Carbon–Carbon Bond Formation Driven by the Rhodium-Catalyzed Water–Gas Shift Reaction
作者:Scott E. Denmark、Malek Y. S. Ibrahim、Andrea Ambrosi
DOI:10.1021/acscatal.6b03183
日期:2017.1.6
The rhodium-catalyzed water–gas shift reaction has been demonstrated to drive the reductive alkylation of several classes of activated methylene compounds at room temperature. Under catalysis by rhodium trichloride (2–3 mol %), carbon monoxide (10 bar), water (2–50 equiv), and triethylamine (2.5–7 equiv), the scope has been successfully expanded to cover a wide range of alkylating agents, including
Solvent-Free, <i>anti</i>-Michael
Addition of Active Methylene Derivatives to β-Nitroacrylates:
Eco-Friendly, Chemoselective Synthesis of Polyfunctionalized Nitroalkanes
The chemoselective, anti-Michael addition of active methylene derivatives to β-nitroacrylates can be easily performed at room temperature, under solvent-free conditions, using a catalytic amount of potassium carbonate as heterogeneous catalyst.
Cooperative Chiral Guanidine/AgPF6 Catalyzed Asymmetric Isocyanoacetate Aldol Reaction with Isatins
作者:Xiaohua Liu、Xiaoming Feng、Yan Lu、Min Wang、Xiaohu Zhao、Lili Lin
DOI:10.1055/s-0034-1380874
日期:——
A cooperative chiral guanidine/Ag(I) catalyst system was developed for the asymmetric isocyanoacetate aldol reaction with isatins. The corresponding chiral spirooxindoleoxazolines were obtained in good yields (up to 99%), moderate diastereoselectivities (up to 88:12 dr) and good enantioselectivities (up to 90% ee).
[EN] NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEASE INHIBITORS<br/>[FR] NOUVEAUX COMPOSES ET COMPOSITIONS UTILISES COMME INHIBITEURS DE PROTEASE
申请人:MERCK FROSST CANADA INC
公开号:WO2001049288A1
公开(公告)日:2001-07-12
The present invention relates to novel cysteine protease inhibitors of Formula (I), the pharmaceutically acceptable salts and N-oxide derivatives thereof, their use as therapeutic agents and methods of making them.